Brunel University Research Archive(BURA) preserves and enables easy and open access to all
types of digital content. It showcases Brunel's research outputs.
Research contained within BURA is open access, although some publications may be subject
to publisher imposed embargoes. All awarded PhD theses are also archived on BURA.
Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/21903Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Li, X | - |
| dc.contributor.author | Sarpong, D | - |
| dc.contributor.author | Wang, CL | - |
| dc.date.accessioned | 2020-11-23T22:28:52Z | - |
| dc.date.available | 2020-11-23T22:28:52Z | - |
| dc.date.issued | 2020-12-18 | - |
| dc.identifier.citation | Li, X., Sarpong, D. and Wang, C.L. (2022) 'Collaborative Strategic Foresight and New Product Development in Chinese Pharmaceutical Firms', IEEE Transactions on Engineering Management, 69 (2), pp. 1 - 13. doi: 10.1109/tem.2020.3040041. | - |
| dc.identifier.issn | 0018-9391 | - |
| dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/21903 | - |
| dc.format.extent | 1 - 13 | - |
| dc.format.medium | Print-Electronic | - |
| dc.language.iso | en | en_US |
| dc.publisher | IEEE | en_US |
| dc.rights | Copyright © 2020 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works. | - |
| dc.rights.uri | https://www.ieee.org/publications/rights/rights-policies.html | - |
| dc.subject | collaborative strategic foresight | en_US |
| dc.subject | open innovation | en_US |
| dc.subject | new product development | en_US |
| dc.subject | Chinese pharmaceutical firms | en_US |
| dc.title | Collaborative Strategic Foresight and New Product Development in Chinese Pharmaceutical Firms | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | https://doi.org/10.1109/tem.2020.3040041 | - |
| dc.relation.isPartOf | IEEE Transactions on Engineering Management | - |
| pubs.issue | 2 | - |
| pubs.publication-status | Published | - |
| pubs.volume | 69 | - |
| dc.identifier.eissn | 1558-0040 | - |
| dc.rights.holder | IEEE | - |
| Appears in Collections: | Brunel Business School Research Papers | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| FullText.pdf | Copyright © 2020 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works. | 1.7 MB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.